Short answer
Protalix BioTherapeutics, Inc. (PLX) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $20M (up 27.1% year over year) with net income of $4M.
Q2 2026 key financials · XBRL
- Revenue
- $20M
- +27.1% YoY · −41.0% QoQ
- Net income
- $4M
- +2203.0% YoY · −79.4% QoQ
- Operating margin
- 23.5%
- EPS (diluted)
- $0.05
- +400.0% YoY · −77.3% QoQ
Source: XBRL data from the Protalix BioTherapeutics, Inc. (PLX) Q2 2026 10-Q on SEC EDGAR. USD.
Protalix BioTherapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $19.896M, up 27% YoY from $15.658M
- Operating margin 23.5% vs 7.5% YoY, based on operating income $4.672M vs $1.172M
- Best performer Chiesi sales $14.035M, up $4.242M YoY
- Worst performer Pfizer sales $4.279M, down $1.368M YoY
- Near-term R&D spending expected to increase with the RELEASE study and advanced candidate trials
Risk Factors
- New tariff risk triggered by April 2, 2026 U.S. Section 232 tariffs on pharmaceutical products, APIs, and starting materials
- Tariffs scheduled for September 2026 could impair U.S. commercialization and financial condition
- New Israeli R&D grant risk under the 2026 R&D Law, with awards subject to Finance Minister discretion
- Carried-forward risks otherwise unchanged from the December 31, 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protalix BioTherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.